



PCT/EP200 4 / 0 0 3 2 3 3



INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 14 MAY 2004

WIPO

PCT


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

Dated

30 January 2004

Patents Form 1/77

Patents Act 1977
(Rule 16)



10 JUL 03 E821433-3 000245
P01/7700 0100-0316087.6

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales NP10 8QQ

1.	Your reference	G-33005P2/BCK 9936		
2.	Patent application number (The Patent Office will fill in this part)	0316087.6		
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	SANDOZ GMBH BIOCHEMIESTRASSE 10 A-6250 KUNDL, TIROL AUSTRIA 8638736001		
	Patent ADP number (if you know it)			
	If the applicant is a corporate body, give the country/state of its incorporation	AUSTRIA		
4.	Title of invention	Organic Compounds		
5.	Name of your agent (if you have one)	Craig McLean		
	"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	Novartis Pharmaceuticals UK Limited Patents and Trademarks Wimbleshurst Road Horsham West Sussex RH12 5AB 7181522002		
	Patents ADP number (if you know it)			
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day/month/year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day/month/year)	
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:	Yes		
	a) any applicant named in part 3 is not an inventor, or			
	b) there is an inventor who is not named as an applicant, or			
	c) any named applicant is a corporate body.			
	(see note (d))			

09 JUL 2003

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 11

Claim(s) 2

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

One ✓

Request for substantive examination (*Patents Form 10/77*)


Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date



9th July 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs. S. Schnerr

01403 323069

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) Once you have filled in the form you must remember to sign and date it.
- e) For details of the fee and ways to pay please contact the Patent Office.

Organic Compounds

This invention relates to pharmaceutical compositions of venlafaxine.

5

Venlafaxine is the non-proprietary name for 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol and is useful in treating a number of disorders including depression, anxiety, panic disorder and pain. Venlafaxine is administered as venlafaxine hydrochloride in treating depression. See The Merck Index, 12th Edition, entry 10079.

10

Published European patent application EP 797 991 A discloses encapsulated extended release formulations of venlafaxine hydrochloride which comprise a hard gelatin capsule containing spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and hydroxypropylmethylcellulose coated with ethyl cellulose and hydroxypropylmethylcellulose.

15

Solvents used in the coating step include methylene chloride and anhydrous methanol.

The present applicants have sought to overcome the drawbacks of hitherto known formulations of venlafaxine.

20

In one aspect, therefore, this invention provides coated core pellets comprising venlafaxine for use in a delayed and/or extended release formulation which core pellets undergo at least one coating step in the absence or substantial absence of organic solvents.

In another aspect, this invention provides a coated pellet comprising

25

a) a pellet core which comprises venlafaxine hydrochloride;

b) a first coating which comprises a lipophilic layer or a sparingly water-soluble layer, and

c) a second coating which comprises a water-soluble or water-insoluble polymer.

30

The pellet core may comprise in addition a carrier, for example microcrystalline cellulose. The pellet core may comprise in addition a binder, for example a cellulose derivative, e.g. hydroxypropylmethylcellulose (HPMC). The present applicants have found that HPMC of e.g. grade K 4 M has an appropriate viscosity for use in this invention.

5

The pellet core may be spheroidal in geometry and typically exhibits a diameter, when coated, of between around 0.5 mm to 2 mm, e.g. 0.7 to 1.75mm, for example 0.8 mm to 1.5 mm.

10

The first coating and second coating may each be complete or substantially complete, e.g. so as to provide a surface coverage of at least 60 %, e.g. 70 % or more, e.g. 80 to 95 % around the core (first coating) or around the first coating (second coating). Complete coatings are preferred.

15

The first coating may comprise between 0.5 to 5% by weight, e.g. 1 to 4%, of the first-coated pellet core.

The second coating may comprise 8 to 30% by weight, e.g. 10 to 25%, based on the total weight of the double-coated core.

20

The first coating serves to protect the pellet core from moisture, both in storage and in use.

The lipophilic layer may comprise a fat, fatty alcohol or wax. The lipophilic layer preferably comprises cetostearyl alcohol, castor oil or dibutyl phthalate.

25

The sparingly water-soluble layer may comprise a carbohydrate or a sugar, e.g. lactose, in the form of an aqueous suspension wherein the concentration of the carbohydrate or sugar is at least about 0.1 g/ml, e.g. 0.15 to 0.25 g/ml or greater, e.g. 0.28 g/ml to 0.4 g/ml or even higher, e.g. 0.41 to 0.6 g/ml, for example 0.43 or 0.5 g/ml.

30

The sparingly water-soluble layer, which may be formed by spray-coating, may comprise lactose in an amount of up to about 30% to 40% by weight.

The water-soluble or water-insoluble polymer may be selected from acrylate-based aqueous dispersions, ethylcellulose aqueous dispersions and polyvinyl acetate aqueous dispersions. Thus the second coating is aqueous-based and serves to provide the extended release effect.

5

Water-insoluble polymers are preferred and may serve to control release of the venlafaxine. The water-insoluble polymer may display pH-independent solubility and may comprise a water-insoluble polymer mixture.

- 10 The term "water-insoluble", as used herein is understood to mean a polymer solubility in water at room temperature of less than 100 mg/litre, e.g. 20 mg/litre or less, e.g. 10mg/litre or less, e.g. 1mg/litre or less.

- 15 In a preferred aspect, the pellet core and/or coating(s) of this invention are free of, or substantially free of, polyvinylpyrrolidone.

In another aspect, this invention provides a composition comprising coated pellets as herein described. The composition may be in tablet, hard gelatine capsule or sachet form.

- 20 In another aspect, this invention provides a coated pellet consisting of or consisting essentially of

- a) a core containing venlafaxine hydrochloride in an amount of between 30 and 60 % by weight, microcrystalline cellulose in an amount of between 40 and 65% by weight, and HPMC K 4 M in an amount of between 0.3 and 0.8% by weight, wherein the respective
25 weights are in relation to the double-coated core;

- b) a first coating containing cetostearyl alcohol in an amount of between 1.0 and 4.0 %, e.g. 1.7 and 3.5 %, by weight of the first-coated pellet core; and

- 30 c) a second coating containing an acrylate-based polymer in an amount of between 9 and 25%, e.g. 9 and 13 %, by weight based on the total weight of the double-coated core, and talc

in an amount of between 2 and 15%, e.g. 3 and 8 %, by weight based on the total weight of the double-coated pellet core.

5 Suitable acrylate-based polymers or water-insoluble polymers having pH-independent solubility are available commercially e.g. from the Röhm company, Germany, under the trade marks EUDRAGIT, SURELEASE or AQUACOAT, e.g. EUDRAGIT NE 30 D, EUDRAGIT RL 30 D, EUDRAGIT RS 30 D or KOLLCOAT SR as dry polymer.

10 The second coating may further comprise triethyl citrate or dibutyl phthalate, e.g. in an amount of 5 to 35%, e.g. 10 to 30 %, by weight of the dry polymer.

15 In a further aspect, this invention provides a composition consisting of or consisting essentially of coated pellets as herein described. The composition may be in tablet, hard gelatine capsule or sachet form.

In a further aspect, this invention provides a process for preparing pellets as herein described which comprises the steps of

20 Ai) forming a pellet core mixture comprising venlafaxine hydrochloride with water or an aqueous solution of a binder,

Aii) extruding and spheronising the mixture, and subsequently drying,

25 Aiii) applying the first coating,

Aiv) applying the second coating, and subsequently sieving so as to obtain coated pellets within the desired size range,

wherein the process is carried out in the absence or substantial absence of any organic solvent at least in the second layer.

Coating steps Aiii) and Aiv) may employ conventional fluidised bed processes. Alternatively, the first coating layer may be applied using a spray melt process or by using a tangential coating process.

- 5 In another embodiment, the first coating layer may be dissolved in an organic solvent medium, e.g. methylene chloride or methanol, and sprayed onto the pellet cores.

In a further aspect, this invention provides a process for preparing pellets as herein described which comprises the steps of

10

Bi) forming a pellet core mixture comprising venlafaxine hydrochloride, microcrystalline cellulose and HPMC with water or an aqueous solution of a binder,

Bii) extruding and spheronising the mixture, and subsequently drying,

15

Biii) collecting the core pellets between 0.8 mm to 1.75 mm for further processing,

Biv) applying the first coating, and

20

Bv) applying the second coating

wherein the process is carried out in the absence or substantial absence of any organic solvent at least in the second layer.

25

Coating steps Biv) and Bv) may employ conventional fluidised bed processes. Alternatively, the first coating layer may be applied using a spray melt process or by using a tangential coating process.

30

A preferred embodiment of each of the above processes is such that the process is carried out in the absence or substantial absence of any organic solvent in both the first coating layer and in the second coating layer.

The venlafaxine hydrochloride is sourced from the Medichem company, Spain. The venlafaxine may be used in any polymorphic form, e.g. in the forms known as Form I or Form II. . The compositions of this invention may be administered to adults in doses ranging from 75 mg to 350 mg venlafaxine per day.

5

Following is a description by way of example only of compositions of this invention.

Example 1

Pellets according to the following composition are prepared and filled into hard gelatin capsules.

5	I	Core pellets	Quantity per capsule (mg)
		venlafaxine HCl	169.70
		microcrystalline cellulose	199.0
		HPMC K 4 M	1.85
10	II	Wax coating	
		cetostearyl alcohol	9.26
	III	Polymer coating	
		Eudragit NE 30 D	56.97
15		talc	28.49
		Total weight of coated pellets	476.90

The core pellets are prepared by mixing the above components with a small amount of water, i.e. enough to form a paste without dissolving the venlafaxine, under I followed by extrusion spheronisation. The wax coating is applied using a fluidised bed process at or close to the melting temperature of the coating layer. The subsequent polymer (sustained release) coat is applied by a fluidised bed process. The resulting coated pellets are sieved so as to obtain a desired pellet size range of between 0.85 mm and 1.75 mm.

Example 2

Pellets are prepared in analogous manner to those in Example 1 with replacement of the wax coating by an aqueous suspension of lactose at a concentration of 0.15 g/ml. The suspension is sprayed onto the cores using a perforated pan or a fluidised bed process.

5

In view of the small amount of water involved in the first coating step, negligible dissolution of venlafaxine takes place and a protective layer is formed between the pellet core and the second coating.

10

Example 3a) and 3b)

Pellets according to the following composition are prepared and filled into hard gelatin capsules.

5	I	Core pellets	Quantity per capsule (mg)
		venlafaxine HCl	169.70
		microcrystalline cellulose	193.27
		HPMC K 4 M	1.85
10	II	Wax coating	
		cetostearyl alcohol	10.03
	III	Polymer coating	
		Eudragit NE 30 D	70.10
15		talc	35.05
		Total weight of coated pellets	480.00

The core pellets are prepared by mixing the above components with a small amount of water, i.e. enough to form a paste without dissolving the venlafaxine, under I followed by extrusion spheronisation. The pellets with size between 0.8mm and 1.75mm are collected. The wax coating is applied using in 3a) a fluidised bed process, and in 3b) tangential coater, at or close to the melting temperature of the coating layer. The subsequent polymer (sustained release) coat is applied by a fluidised bed process.

Example 4a) and 4b)

Pellets are prepared in analogous manner to those in Example 1 with replacement of the wax coating by an aqueous suspension of lactose at a concentration of 0.43 g/ml. The suspension

5 is sprayed onto the cores using

4a) a perforated pan, or

4b) a fluidised bed process.

In view of the small amount of water involved in the first coating step, negligible dissolution
10 of venlafaxine takes place and a protective first layer is formed between the pellet core and the second coating.

Example 5

15 A capsule composition is prepared in analogous manner to that in Example 1 with the following component amounts.

20	I	Core pellets	<u>Quantity in %</u>
		venlafaxine HCl	37.3 % by weight of core pellets
		microcrystalline cellulose	62.1 % by weight of core pellets
		HPMC K 4 M	0.5 % by weight of core pellets

25	II	Wax coating	
		cetostearyl alcohol	2.5 % by weight of core pellets

30	III	Polymer coating	
		Eudragit NE 30 D (dry)	15% by weight of pellets with first coating
		talc	50% by weight of dry polymer

The following dissolution profiles are observed using USP Apparatus 1 at 100 rpm in purified water at 37°C.

5	Time (hours)	Cumulative amount dissolved (%)		Dissolution range in %
		EFFEXOR ER	Formulation of Example 3	
	2	14	8	< 30
	4	40	32	30 to 55
10	8	67	68	56 to 80
	12	79	85	65 to 90
	24	93	98	> 80

15

The principal advantages of the pellets and compositions of the present invention include a release profile of venlafaxine as effective as the commercially available product, however without the use of an organic solvent medium at least for application of the second coating. A further advantage is the absence of any organic solvent residue in the coated pellets.

20

The process is more cost-effective and less hazardous than hitherto known processes.

The coated pellets of this invention are thus produced using more economically and environmentally attractive processes than hitherto known processes for venlafaxine.

25

Claims

1. A coated pellet comprising
 - a) a pellet core which comprises venlafaxine hydrochloride;
 - 5 b) a first coating which comprises a lipophilic layer or a sparingly water-soluble layer, and
 - c) a second coating which comprises a water-insoluble polymer or polymer mixture.
2. A pellet as claimed in claim 1 wherein the core additionally comprises a carrier, e.g. microcrystalline cellulose.
- 10 3. A pellet as claimed in claim 1 or claim 2 wherein the core further comprises a binder.
4. A pellet as claimed in claim 3 wherein the binder comprises a cellulose derivative.
- 15 5. A pellet as claimed in claim 3 or claim 4 wherein the binder comprises hydroxypropyl methylcellulose (HPMC).
6. A pellet as claimed in claim 1 or claim 2 wherein the lipophilic layer comprises a fat, fatty alcohol or wax.
- 20 7. A pellet as claimed in any preceding claim wherein the lipophilic layer comprises cetostearyl alcohol, castor oil or dibutyl phthalate.
8. A pellet as claimed in claim 1 or claim 2 wherein the sparingly water-soluble layer
25 comprises a sugar, e.g. lactose, in the form of an aqueous suspension wherein the concentration of the sugar is at least 0.3 g/ml.
9. A pellet as claimed in any preceding claim wherein the water-insoluble polymer is
30 selected from polymethacrylate dispersions, ethylcellulose dispersions and polyvinyl acetate dispersions.

10. A composition comprising pellets as claimed in any preceding claim.

11. A composition as claimed in claim 10 in tablet, hard gelatine capsule or sachet form.

5 12. A process for preparing coated pellet cores which process comprises the steps of

i) forming a pellet core mixture comprising venlafaxine hydrochloride with water or an aqueous solution of a binder,

10 ii) extruding and spheronising the mixture, drying and sieving,

iii) applying a first coating, and

iv) applying a second coating,

15

wherein the process is carried out in the absence or substantial absence of any organic solvent medium at least in the second coating.

13. A process as claimed in claim 12 wherein the pellet core mixture further comprises
20 microcrystalline cellulose and HPMC.

14. A process as claimed in claim 12 or claim 13 wherein the process is carried out in the absence or substantial absence of any organic solvent medium in both the first and second coatings.

25

15. A coated pellet produced by the process as claimed in any one of claims 12 to 14.

16. A pellet, composition or process substantially as herein described with particular reference to the Examples.

30

PCT/EP2004/003255

